You would think that a company posting roughly double the industry
average revenue growth rate and solid margins should be one of the more
highly-valued companies in the sector. Alas, that's not the case with
Covidien (COV).
While I don't want to leave readers with the impression that Covidien's
stock has been completely ignored or trades at an insultingly cheap
multiple, I'm nevertheless surprised that investors haven't shown more
love for one of the more durable growth stories in med-tech.
Please read more here:
What's Wrong With Covidien?
No comments:
Post a Comment